Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;33(5):e13544.
doi: 10.1111/dth.13544. Epub 2020 Jul 1.

COVID-19 with dermatologic manifestations and implications: An unfolding conundrum

Nawaf Almutairi  1 , Robert A Schwartz  1
Affiliations

COVID-19 with dermatologic manifestations and implications: An unfolding conundrum

Nawaf Almutairi et al. Dermatol Ther. 2020 Sep.

Abstract

The novel coronavirus SARS-CoV-2 has caused Coronavirus Disease 2019, widely known as COVID-19, now a pandemic with extraordinary infectivity, mortality, and fomite adhesiveness. We delineate cutaneous manifestations of COVID-19, some of which may represent adverse cutaneous drug reactions, and skin changes associated with COVID-19 lifestyle alterations in patients and health care workers. We review COVID-19 from both a dermatologic and public health perspective.

Keywords: drug reaction; infection-bacterial/fungal/viral; inflammatory disorders; skin signs of systemic disease; therapy-topical; urticaria.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Urticaria in COVID‐19 patient
FIGURE 2
FIGURE 2
A and B, Varicella‐like vesicles in COVID‐19 patient
FIGURE 3
FIGURE 3
A and B, Transient livedoid eruptions in COVID‐19 patients
FIGURE 4
FIGURE 4
A and B, Livedoid vasculopathy in COVID‐19 patient
FIGURE 5
FIGURE 5
A and B, Purpuric eruption in COVID‐19 patient
FIGURE 6
FIGURE 6
Purpuric eruption in COVID‐19 patient
FIGURE 7
FIGURE 7
Purpuric eruption in COVID‐19 patient
FIGURE 8
FIGURE 8
Lichenoid photodermatitis in COVID‐19 patient
FIGURE 9
FIGURE 9
A and B, Erythroderma in COVID‐19 patient
FIGURE 10
FIGURE 10
A and B, Photo‐contact dermatitis in COVID‐19 patient
FIGURE 11
FIGURE 11
A‐D, Generalized pustular figurate erythema in COVID‐19 patient
FIGURE 12
FIGURE 12
Contact urticaria
FIGURE 13
FIGURE 13
Contact dermatitis due to prolonged use of PPE, face
FIGURE 14
FIGURE 14
Irritant contact dermatitis, hands
FIGURE 15
FIGURE 15
A and B, Contact dermatitis, hands
See this image and copyright information in PMC

References

    1. Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, Ippolito G, Mchugh TD, Memish ZA, Drosten C, Zumla A, Petersen E. The continuing 2019‐nCoV epidemic threat of novel coronaviruses to global health – The latest 2019 novel coronavirus outbreak in Wuhan, China Int J Infect Dis 2020;91:264–266. - PMC - PubMed
    1. Jewell NP, Lewnard JA, Jewell BL. Caution warranted: using the Institute for Health Metrics and Evaluation Model for predicting the course of the COVID‐19 pandemic. Ann Intern Med. 2020. 10.7326/M20-1565. - DOI - PMC - PubMed
    1. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708‐1720. 10.1056/NEJMoa2002032. - DOI - PMC - PubMed
    1. Ippolito G, Hui DS, Ntoumi F, Maeurer M, Zumla A. Toning down the 2019‐nCoV media hype‐and restoring hope. Lancet Respir Med. 2020;8(3):230‐231. 10.1016/S2213-2600(20)30070-9. - DOI - PMC - PubMed
    1. Yen MY, Schwartz J, Chen SY, King CC, Yang GY, Hsueh PR. Interrupting COVID‐19 transmission by implementing enhanced traffic control bundling: implications for global prevention and control efforts. J Microbiol Immunol Infect. 2020. 10.1016/j.jmii.2020.03.011. - DOI - PMC - PubMed

Substances